[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity
DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
[HTML][HTML] An update on peptide-based therapies for type 2 diabetes and obesity
Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1)
and those modified to interact also with receptors for glucose-dependent insulinotropic …
and those modified to interact also with receptors for glucose-dependent insulinotropic …
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active …
DCW Lau, L Erichsen, AM Francisco, A Satylganova… - The Lancet, 2021 - thelancet.com
Background Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a
long-acting amylin analogue under investigation for weight management. We assessed the …
long-acting amylin analogue under investigation for weight management. We assessed the …
Derivatization with fatty acids in peptide and protein drug discovery
P Kurtzhals, S Østergaard, E Nishimura… - Nature Reviews Drug …, 2023 - nature.com
Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …
often have to be injected and their effects are short-lived. These shortcomings of the native …
Elucidating the interactome of G protein-coupled receptors and receptor activity-modifying proteins
G protein-coupled receptors (GPCRs) are known to interact with several other classes of
integral membrane proteins that modulate their biology and pharmacology. However, the …
integral membrane proteins that modulate their biology and pharmacology. However, the …
A structural basis for amylin receptor phenotype
Amylin receptors (AMYRs) are heterodimers of the calcitonin (CT) receptor (CTR) and one of
three receptor activity–modifying proteins (RAMPs), AMY1R, AMY2R, and AMY3R. Selective …
three receptor activity–modifying proteins (RAMPs), AMY1R, AMY2R, and AMY3R. Selective …
[HTML][HTML] Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022
HE Bays, A Fitch, S Christensen, K Burridge, J Tondt - Obesity Pillars, 2022 - Elsevier
Abstract Background This “Anti-Obesity Medications and Investigational Agents: An Obesity
Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an …
Medicine Association Clinical Practice Statement 2022” is intended to provide clinicians an …
Structural insight into selectivity of amylin and calcitonin receptor agonists
Amylin receptors (AMYRs), heterodimers of the calcitonin receptor (CTR) and one of three
receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR …
receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR …
Recent advances in the development of therapeutic peptides
Peptides have unique characteristics that make them highly desirable as therapeutic agents.
The physicochemical and proteolytic stability profiles determine the therapeutic potential of …
The physicochemical and proteolytic stability profiles determine the therapeutic potential of …
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: translational difficulties and pitfalls
L Simonsen, J Lau, T Kruse, T Guo, J McGuire… - PLoS …, 2022 - journals.plos.org
During recent years combining GLP-1 and glucagon receptor agonism with the purpose of
achieving superior weight loss and metabolic control compared to GLP-1 alone has …
achieving superior weight loss and metabolic control compared to GLP-1 alone has …